Pharmaceuticals · NYSE

ZTSZoetis Inc.

Last close
$83.82 +1.0%
52-week range
$68.77 to $132.49
Market cap
$34.1B
Next earnings
Not scheduled

Fiscal 2025 at a glance

Revenue
$9.47B
+2% vs FY24
Net income
$2.67B
+8% vs FY24
Free cash flow
$2.28B
-1% vs FY24
Net cash
-$6.59B
Cash $2.45B, debt $9.04B

Stock price

+62% since Dec 2016

Valuation vs its own 10 years

Below its 10-year median on all 4 multiples

Where each multiple sits today inside its own range since 2016, measured at every quarter end. The thin tick is the median.

P/E, trailing
14.1x
11.7x57.1x
5th percentile, below its median of 35.8x
Price / sales
3.6x
3.0x14.9x
5th percentile, below its median of 8.8x
EV / EBITDA
10.8x
9.3x37.7x
5th percentile, below its median of 23.0x
Price / free cash flow
15.2x
12.9x66.9x
5th percentile, below its median of 44.2x

Key statistics

Trailing 12 months unless noted, through the quarter ending 2026-09-30. Every figure carries its unit.

Valuation

P/E
14.1x
Earnings yield
7.1%
Price / sales
3.6x
Price / book
10.3x
Price / operating cash flow
12.5x
EV / EBITDA
10.8x
EV / sales
4.4x
Free cash flow yield
6.6%

Profitability

Gross margin
71.6%
Operating margin
n/a
Net margin
26.4%
Return on equity
75.9%
Return on capital
n/a

n/a: Not reported

Growth per year

Revenue, 3 years
+5.4%
Revenue, 5 years
+7.2%
Revenue, 9 years
+7.6%
EPS, 3 years
+10.3%

Balance sheet

Cash and investments
$1.53B
Total debt
$9.05B
Net cash
-$7.52B
Debt / equity
2.74x
Current ratio
2.35x

Shares and dividend

Shares outstanding
406M
Share count, 5 years
-7.3%
Beta, 1 year
0.61
Dividend yield
2.5%
Dividend per share, TTM
$2.09
Payout ratio
n/aNot meaningful

Ten years of the business

Last 40 quarters, fiscal 2016 to 2025 and after. Hover a bar for its quarter.

Revenue and net incomeLatest quarter $2.39B
RevenueNet income
Gross profitLatest quarter $1.69B
EBITDALatest quarter $910M
Margins71 / 25%
GrossOperatingNet
Earnings per shareLatest quarter $1.44
Cash flowLatest quarter $824M
OperatingCapexFree
Cash vs debtLatest quarter $1.53B
Cash and investmentsTotal debt
P/E historyNow 14.1x
P/E, median 35.8x dashed
P/S historyNow 3.6x
P/S, median 8.8x dashed

Where the revenue comes from

Dermatology went from 16% to 19% of revenue in 3 years

Share of revenue by product line, fiscal 2022 to 2025, as reported in the 10-K.

ParasiticidesVaccinesDermatologyCattlePain SedationOther PharmaceuticalsSwine
FY22
23%21%16%18%
$8.08B
FY23
23%21%17%18%
$8.54B
FY24
23%20%18%17%9%
$9.26B
FY25
25%21%19%16%9%
$9.47B
Fiscal 2025 by product line
Product lineRevenueSharevs FY24
Parasiticides$2.34B24.7%+9%
Vaccines$1.96B20.7%+7%
Dermatology$1.75B18.5%+6%
Cattle$1.49B15.8%-3%
Pain Sedation$840M8.9%-1%
Other Pharmaceuticals$697M7.4%+6%
Swine$466M4.9%n/a

Pharmaceuticals peers

The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.

CompanyMarket capRevenue growth Operating marginP/EP/SP/E vs own history
LLY ELI LILLY & Co $1.36T +46% n/a46.8x15.7x 60th percentile
JNJ Johnson & Johnson $688B +8% n/a43.4x6.9x 90th percentile
MRK Merck & Co., Inc. $364B +5% n/a152x5.4x 98th percentile
PFE Pfizer Inc $165B +1% n/a41.2x2.6x 97th percentile
BMY Bristol Myers Squibb Co $130B +4% n/a14.1x2.6x 13th percentile
ZTS Zoetis Inc. $34.1B +1% n/a14.1x3.6x 5th percentile

The company

Sector
Health Care
Industry
Pharmaceuticals
Founded
1952
Headquarters
Parsippany, NJ
Fiscal year ends
December
Website
zoetis.com

What it does

Zoetis Inc., headquartered in Parsippany, New Jersey, is the largest producer of medicine and vaccinations for pets and livestock worldwide.

Description from Wikipedia (CC BY-SA).

Around the numbers

What the rest of EdgeStacker knows about ZTS.

Next report

No confirmed report date in the next 95 days yet.

Open the Earnings Hub
Big funds, latest 13F

Held by 1,115 active funds. Crowd level: quiet.

Open the Smart money tab